Details, Fiction and XMU-MP-1
Kantarjian et al53 assessed the efficacy and protection of dasatinib, as when compared with imatinib, for the very first-line cure of CML-CP. Five hundred and nineteen people with newly diagnosed CML-CP ended up randomly assigned to receive dasatinib at a dose of a hundred mg when each day (259 individuals) or imatinib in a dose of 400 mg when day